Trolamine

Trolamine

SCHEMBL671041

CCCCCCCCCCCCc1ccccc1.OCCN(CCO)CCO

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.68
OPRM1 P35372 4/20 0.56
DRD3 P35462 4/20 0.56
DRD2 P14416 3/20 0.56
OPRD1 P41143 3/20 0.56
OPRK1 P41145 3/20 0.56
SIGMAR1 Q99720 4/20 0.56
ADRA2A P08913 3/20 0.53
SLC6A2 P23975 3/20 0.53
SLC6A4 P31645 3/20 0.53
SLC6A3 Q01959 3/20 0.53
CHRM2 P08172 2/20 0.53
CHRM1 P11229 2/20 0.53
HTR1A P08908 1/20 0.53
DRD1 P21728 1/20 0.53
ADRA1A P35348 1/20 0.53
THRA P10827 2/20 0.51
THRB P10828 2/20 0.51
ESR1 P03372 2/20 0.50
ADORA3 P0DMS8 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trolamine SCHEMBL11590482 1.00 KCNH2 (0.68) KCNH2OPRM1DRD3DRD2OPRD1
Trolamine SCHEMBL28434418 0.98 KCNH2 (0.66) KCNH2OPRM1DRD3DRD2OPRD1
Trolamine SCHEMBL691941 0.92 KCNH2 (0.59) KCNH2OPRM1DRD3DRD2OPRD1
Butane SCHEMBL23824784 0.89 KCNH2 (0.61) KCNH2SIGMAR1ADRA2ASLC6A2SLC6A4
Hydrochloric Acid SCHEMBL5053406 0.89 OPRM1 (0.68) KCNH2OPRM1DRD3DRD2OPRD1
SCHEMBL11134742 0.87 KCNH2 (0.86) KCNH2OPRM1DRD3DRD2OPRD1
SCHEMBL11237058 0.87 KCNH2 (0.86) KCNH2OPRM1DRD3DRD2OPRD1
SCHEMBL8086575 0.87 KCNH2 (0.59) KCNH2OPRM1DRD3SIGMAR1ADRA2A
SCHEMBL11135856 0.87 KCNH2 (0.86) KCNH2OPRM1DRD3DRD2OPRD1
SCHEMBL29107066 0.87 KCNH2 (0.86) KCNH2OPRM1DRD3DRD2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024072942-A2 SKIN PENETRATING FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS ADORA ANIMAL HEALTH CORPORATION (US) 2024-04-04 WO claimed
US-20240101495-A1 A SOLUBILIZING COMPOSITION ORO AGRI INC. 2024-03-28 US claimed
US-20230329987-A1 Sulfate-Free Surfactant System ETHOX CHEMICALS, LLC 2023-10-19 US claimed
WO-2023180932-A1 AGRICULTURAL COMPOSITION ORO AGRI EUROPE, S.A. (PT) 2023-09-28 WO claimed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 EP claimed
US-11692107-B1 Graffiti removal system ETHOX CHEMICALS, LLC (US) 2023-07-04 US claimed
US-20230172200-A1 A LIQUID ANTI-PATHOGENIC AGRICULTURAL COMPOSITION ORO AGRI INC. 2023-06-08 US claimed
US-20230157280-A1 A LIQUID AGRICULTURAL ADJUVANT ORO AGRI INC. 2023-05-25 US claimed
US-20230053399-A1 AN AGRICULTURAL ADJUVANT ORO AGRI INC. 2023-02-23 US claimed
US-20230053407-A1 Sulfate-Free Surfactant System FIRST NATIONAL BANK OF PENNSYLVANIA 2023-02-23 US claimed
WO-2009012546-A1 BLOCKING COMPOSITION AGAINST FIRE ACTION AND ADVANCE IN DIVERSE SURFACES, MANUFACTURING AND APPLICATION PROCESS THEREOF RADIX ASSESSORIA E CONSULTORIA LTDA. (BR) 2009-01-29 WO claimed
US-20080233053-A1 nebulizer; eye-state detector, open or shut; reversibly actuatable radiation-source of sterilizing radiation; contactor for posterior eye; shut eye; vibrate eyelid; increase bioavailability to sclera, optic nerve, retina, brain, central nervous system, cerebral cavity, cerebrospinal fluid, spinal cord PHARMALIGHT INC. (DE) 2008-09-25 US claimed
EP-1848541-A2 METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS Pharmalight Inc. (US) 2007-10-31 EP claimed
WO-2006082588-A2 METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS PHARMALIGHT INC. (US) 2006-08-10 WO claimed
US-20020119113-A1 SHAMPOO COMPOSITIONS UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-08-29 US claimed
EP-1126819-A1 SHAMPOO COMPOSITIONS UNILEVER PLC (GB) 2001-08-29 EP claimed
EP-0586519-B1 METHOD OF TREATING SOIL SOTAC CORP (US) 2000-09-13 EP claimed
WO-2000025741-A1 SHAMPOO COMPOSITIONS UNILEVER PLC (GB) 2000-05-11 WO claimed
US-5523081-A MIXTURE OF WATER, SOAP AND POLYSILOXANE MICROEMULSION CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) 1996-06-04 US claimed
US-4272495-A Chemical processes WOODSREEF MINES LIMITED (AU) 1981-06-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230329987-A1 Sulfate-Free Surfactant System STS, DLST, MPST KCNH2 2600/4885OPRM1 3657/4885DRD3 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.